AbbVie ESMO 2026: Structural Pipeline Maturity Visible, But Mechanism Opacity Blocks Conviction

AbbVie Highlights Solid Tumor Portfolio Progress at ESMO 2026

AbbVie announced new and updated data from its extensive solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from October 23-27. The presentations will feature seven assets, including investigational and approved medicines like Temab-A, ABBV-706, and ABBV-969, across various tumor types and development stages. Key findings highlight encouraging clinical activity, longer-term survival, and promising outcomes in biomarker-defined patient populations, underscoring AbbVie's commitment to advancing differentiated oncology treatments.

• Updated Phase 1 data for Temab-A, a c-Met-directed ADC, demonstrated encouraging clinical activity across multiple solid tumor types. In advanced colorectal cancer, Temab-A combined with bevacizumab achieved a 30% overall response rate and a median overall survival of 14.7 months. For non-squamous non-small cell lung cancer, monotherapy showed a 50% ORR in EGFR wild-type patients and 63% in EGFR-mutant patients, with a 37% intracranial ORR in EGFR-mutant patients with brain metastases.
• Phase 1 findings for ABBV-706, a SEZ6-directed ADC, reinforced its potential in relapsed/refractory small cell lung cancer. At the selected Phase 3 dose, it achieved a 56% overall response rate and 12.4 months median overall survival in heavily pre-treated patients. Notably, in the second-line only subset, the ORR increased to 82% with a median OS of 14.4 months, supporting its ongoing Phase 3 evaluation.
• Biomarker findings from a Phase 1 study of ABBV-969, a dual-targeting ADC for PSMA and STEAP1, showed robust molecular responses in metastatic castration-resistant prostate cancer. By cycle 3, 90% of patients achieved a ≥50% reduction in circulating tumor DNA, and 78% experienced circulating tumor cell conversion, supporting its continued clinical development to address tumor heterogeneity.

Temab-A's Encouraging Efficacy in Advanced Colorectal Cancer

Recent clinical evidence across multiple studies highlights meaningful advances in the treatment of colorectal cancer (CRC), spanning immunotherapy combinations, targeted agents, and conversion regimens. The findings below reflect key efficacy and safety data from several trials and analyses.

• KEYNOTE-164 (Pembrolizumab): In previously treated MSI-H/dMMR advanced CRC, pembrolizumab 200 mg every 3 weeks demonstrated an ORR of 32.8% (95% CI, 21.3%–46.0%) in cohort A (≥2 prior therapies) and 34.9% (95% CI, 23.3%–48.0%) in cohort B (≥1 prior therapy), with median follow-up of 62.2 and 54.4 months, respectively. Median DOR was not reached in either cohort. Median OS was 31.4 months (95% CI, 21.4–58.0) in cohort A and 47.0 months (95% CI, 19.2–NR) in cohort B. No new safety signals were observed.

• Nivolumab plus Ipilimumab in MSI-H/dMMR CRC (Systematic Review): A systematic review of six studies (N = 758) — comprising four phase II trials, one phase III randomised trial, and one phase II neoadjuvant trial — reported ORRs of 31–69% with durable PFS and OS benefits, particularly in metastatic settings. Grade 3–4 treatment-related adverse events occurred in 14–35% of patients, with diarrhoea, fatigue, and endocrinopathies among the most commonly reported.

• CAVE Trial (Cetuximab plus Avelumab): This single-arm, multicenter phase 2 trial evaluated cetuximab rechallenge plus avelumab in pretreated RAS wild-type mCRC patients. The study met its primary endpoint, with a median OS of 11.6 months (95% CI, 8.4–14.8 months) and a median PFS of 3.6 months (95% CI, 3.2–4.1 months). Patients with RAS/BRAF wild-type ctDNA achieved a median OS of 17.3 months (95% CI, 12.5–22.0 months) versus 10.4 months (95% CI, 7.2–13.6 months) in those with mutated ctDNA (HR, 0.49; 95% CI, 0.27–0.90; P = .02). Common grade 3 adverse events were cutaneous eruption (14%) and diarrhoea (4%).

• TRICE Trial (Cetuximab plus FOLFOXIRI vs. Cetuximab plus FOLFOX): In 146 RAS/BRAF wild-type CRC patients with initially unresectable colorectal liver metastases, ORR was comparable between the triplet and doublet arms (84.7% vs. 79.7%; OR 0.70; 95% CI, 0.30–1.67; p = 0.42). Median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (HR 0.74; 95% CI, 0.50–1.11; p = 0.14). The triplet arm was associated with higher rates of grade ≥3 neutropenia (44.1% vs. 27.0%; p = 0.03) and diarrhoea (5.9% vs. 0%; p = 0.03).

• Triple Therapy Meta-Analysis — Encorafenib, Cetuximab, and Binimetinib (BRAF V600E-Mutated CRC): A systematic review and meta-analysis of six studies (487 patients) reported a pooled median OS of 9.75 months (95% CI: 7.22–15.69), a 12-month OS rate of 44% (95% CI: 29–66%), a median PFS of 4.89 months (95% CI: 4.22–6.46), and an ORR of 35% (95% CI: 27–44%), including a 5% complete response rate and a 32% partial response rate. Grade ≥3 adverse events occurred in 46% of patients, most commonly acneiform dermatitis and diarrhoea.

Temab-A's Safety Profile and Potential in NSCLC

Across its studied indications, Temab-A has demonstrated a broadly manageable safety profile, with treatment-emergent adverse events (TEAEs) observed universally across enrolled patients. In the phase 1 study of 122 patients with metastatic colorectal cancer (mCRC), all patients experienced at least one TEAE, with gastrointestinal toxicities (78%) and hematologic toxicities (71%) representing the most frequent categories. Treatment-related discontinuations and deaths were infrequent, occurring in 10% and 3% of patients, respectively. The maximum tolerated dose was established at 3.0 mg/kg once every 3 weeks, with 2.4 mg/kg once every 3 weeks identified as having a tolerable and manageable safety profile alongside promising antitumor activity.

In patients with advanced gastric/gastroesophageal junction adenocarcinoma (GEA), Temab-A monotherapy at 3.0 mg/kg Q3W was evaluated in 42 patients over a median follow-up of 12.6 months. All patients experienced one or more TEAEs, with 88% reporting grade ≥3 TEAEs — a notably higher rate of severe events compared to the mCRC cohort. The most common hematologic TEAEs were anemia (67%), nausea (52%), and decreased appetite (36%). Despite this toxicity burden, the safety profile was characterised as manageable, and the findings were considered supportive of further clinical development, particularly in combination regimens for patients with 2L+ GEA.

Taken together, the safety data across both indications indicate that gastrointestinal and hematologic toxicities represent the primary adverse event classes associated with Temab-A, consistent with its topoisomerase 1 inhibitor payload mechanism. The differential rate of grade ≥3 TEAEs between the mCRC and GEA populations — and the dose-dependent tolerability observed in mCRC — underscores the importance of dose optimisation in ongoing and future development. The phase 3 AndroMETa-CRC-560 trial, evaluating Temab-A plus bevacizumab, will provide further characterisation of the long-term safety profile in a larger, prospectively defined population.

Addressing Unmet Needs in Relapsed Colorectal Cancer

Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide, and despite advances in surgery, chemotherapy, and targeted therapy, significant therapeutic gaps persist — particularly in the metastatic setting. Approximately 50% of patients develop metastases during treatment, and primary tumor recurrence occurs in 50% of patients receiving standard-of-care modalities, underscoring the urgent need for more durable treatment strategies.

• Limited efficacy of immune checkpoint inhibitors (ICIs) in the majority of CRC patients. ICIs have transformed outcomes for the ~5% of patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors. However, the vast majority (~95%) of metastatic CRC cases are mismatch repair-proficient (pMMR) or microsatellite stable (MSS), characterized by low tumor mutational burden, sparse immune infiltration, and an immunosuppressive tumor microenvironment — features that render these "cold tumors" generally insensitive to single-agent ICI therapy.

• Rapid emergence of resistance to targeted therapies. Targeted therapies directed at EGFR, BRAF V600E, KRAS G12C, and amplified HER2 are limited by rapid resistance development. Baseline disease burden (≥3 vs. <3 sites), the presence of hepatic metastases, and gene amplification at baseline were each associated with shorter time on treatment. At resistance, copy-number changes and a high number (≥5) of acquired alterations were also associated with shorter time on treatment. Mechanisms of resistance to anti-EGFR therapy include KRAS, NRAS, BRAF V600E, AKT1, PIK3CA mutations, and ERBB2 or FGFR1 amplifications, with cetuximab exposure dramatically selecting for rare resistant subclones initially undetectable at baseline.

• Complexity of BRAF mutation classes and differential treatment response. Non-V600 BRAF mutations present a clinically heterogeneous landscape. Class 2 BRAF mutants (activating, RAS-independent) showed a response rate of only 8% to anti-EGFR therapy, whereas class 3 BRAF mutants (kinase-impaired, RAS-dependent) achieved a 50% response rate (P = 0.02). For BRAF V600E tumors, resistance to combined RAF and EGFR inhibition converges on RAF dimerization, with wild-type RAS amplification identified as a recurrent resistance mechanism specific to colorectal cancer and not observed in similarly resistant melanomas.

• Inflammatory conditions undermining ICI efficacy even in MSI-H tumors. Inflammatory conditions correlate with poor tumor response to PD-1 blockade in MSI-H CRCs. An elevated neutrophil-to-lymphocyte ratio indicates inhibited immune status and poor tumor response to ICIs, with neutrophil leukocytes implicated via CD80/CD86-CTLA4 signaling in the suppressive immune microenvironment. Combined use of inflammatory conditions and high neutrophil-to-lymphocyte ratio as predictors further increases the predictive value for poor ICI response.

• Challenges in oxaliplatin-based chemotherapy delivery. Oxaliplatin (l-OHP), approved in combination with 5-FU/leucovorin (FOLFOX) for first- and second-line metastatic CRC, is limited by dose-limiting cumulative neurotoxicity, acute dysesthesias, nonselective accumulation in healthy tissues, inactivation by conjugation with glutathione, and the development of drug resistance — all of which constrain its clinical utility.

• Pharmacokinetic variability in 5-FU dosing. Standard body surface area (BSA)-based dosing of 5-fluorouracil produces wide plasma-level variations. Pharmacokinetic (PK) dosing has been associated with improved outcomes — median OS of 19.6 months for PK versus 14.6 months for BSA for 5-FU plus folinic acid, and 27.4 months for PK versus 20.6 months for BSA for FOLFOX6 in metastatic CRC — yet no randomized controlled trials using current regimens have been conducted to confirm these findings, leaving considerable uncertainty about evidence quality and practical implementation.

AbbVie's ADC Portfolio: Advancing Precision Oncology in Solid Tumors

AbbVie's upcoming presentations at ESMO 2026 signal a pivotal moment for its oncology portfolio, particularly in the burgeoning field of antibody-drug conjugates (ADCs). The spotlight on Telisotuzumab Vedotin (Teliso-V) is significant, building on its recent accelerated FDA approval for c-Met-high, EGFR wild-type non-small cell lung cancer (NSCLC). This approval underscores the growing importance of biomarker-driven therapies and positions Teliso-V as a first-in-class option for a previously underserved patient population. Clinical data consistently show Teliso-V's encouraging antitumor activity and a manageable safety profile, primarily characterized by peripheral neuropathy, which is a known class effect for ADCs with monomethyl auristatin E (MMAE) payloads.

Beyond NSCLC, AbbVie is showcasing ABBV-706, a SEZ6-targeting ADC, which has demonstrated promising preliminary efficacy with high objective response rates in relapsed/refractory small cell lung cancer (SCLC). This asset could offer a much-needed therapeutic advance in a disease notoriously difficult to treat. Furthermore, the inclusion of ABBV-969, a dual PSMA/STEAP1-targeted ADC for metastatic castration-resistant prostate cancer (mCRPC), highlights AbbVie's strategic diversification within the ADC landscape, exploring novel targets and combination strategies to address complex solid tumors.

However, the path forward is not without considerations. The successful integration of these ADCs into clinical practice will depend on:

• Refined biomarker diagnostics: Ensuring accurate identification of patients most likely to benefit.

• Proactive toxicity management: Mitigating common ADC-related adverse events like neuropathy and anemia.

• Confirmatory trial success: Especially for accelerated approvals like Teliso-V, demonstrating long-term survival benefits in larger studies is paramount for full regulatory endorsement and sustained market presence.

AbbVie's robust ADC pipeline and strategic focus on molecularly defined patient populations position it as a key player in shaping the future of precision oncology.